Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Autor: Rafael Rosell, Alice T. Shaw, Ali Zeaiter, Shirish M. Gadgeel, Emmanuel Mitry, Bogdana Balas, Jin S. Ahn, Maurice Perol, Johannes Noe, Sai-Hong Ignatius Ou, Peter N. Morcos, D. Ross Camidge, Solange Peters, Tony Mok, Dong Wan Kim, Rafal Dziadziuszko, Sophie Golding

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
The New England journal of medicine, vol. 377, no. 9, pp. 829-838

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d35d488c552e94e96cbf18b7922921
https://doi.org/10.1056/nejmoa1704795

Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.

Autor: Kott KA; Cardiovascular Discovery Group, Kolling Institute of Medical Research, University of Sydney, St Leonards 2065, Australia.; Department of Cardiology, Royal North Shore Hospital, St Leonards 2065, Australia.; Sydney Medical School, University of Sydney, Camperdown 2050, Australia., Bishop M; School of Medicine and Public Health, University of Newcastle, Kensington 2033, Australia., Yang CHJ; Sydney Medical School, University of Sydney, Camperdown 2050, Australia., Plasto TM; Sydney Medical School, University of Sydney, Camperdown 2050, Australia., Cheng DC; Sydney Medical School, University of Sydney, Camperdown 2050, Australia., Kaplan AI; Sydney Medical School, University of Sydney, Camperdown 2050, Australia., Cullen L; Emergency and Trauma Centre, Royal Brisbane and Women's Hospital, Herston 4029, Australia., Celermajer DS; Sydney Medical School, University of Sydney, Camperdown 2050, Australia.; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown 2050, Australia.; The Heart Research Institute, Newtown 2042, Australia., Meikle PJ; Baker Heart and Diabetes Institute, Melbourne 3004, Australia., Vernon ST; Cardiovascular Discovery Group, Kolling Institute of Medical Research, University of Sydney, St Leonards 2065, Australia.; Department of Cardiology, Royal North Shore Hospital, St Leonards 2065, Australia.; Sydney Medical School, University of Sydney, Camperdown 2050, Australia., Figtree GA; Cardiovascular Discovery Group, Kolling Institute of Medical Research, University of Sydney, St Leonards 2065, Australia.; Department of Cardiology, Royal North Shore Hospital, St Leonards 2065, Australia.; Sydney Medical School, University of Sydney, Camperdown 2050, Australia.

Publikováno v: Cells [Cells] 2022 Feb 08; Vol. 11 (3). Date of Electronic Publication: 2022 Feb 08.